Morria presents promising skin drug data

“I believe these results are very promising and may provide a much needed alternative to current topical treatments such as corticosteroids,” said Professor Arieh Ingber, the head of the Department of Dermatology at Hadassah Hospital.

The pilot clinical study findings show that a topical preparation of the drug MRX1, applied twice daily for 14 days, scored 69% improvement based on conventional Physician's Assessment versus a standard 30% placebo effect generated by the moisturizing vehicle.

“Our aim is to continue expanding in the inflammatory skin disease area as well as accelerate our parallel program in the respiratory field and in gastro-intestinal inflammation,” said Dr Yuval Cohen, managing director of Morria Biopharmaceuticals.

“We expect more clinical trials in these fields to commence in the near future.”